First Light Asset Management LLC Purchases Shares of 2,462,448 Endologix, Inc. (NASDAQ:ELGX)

Share on StockTwits

First Light Asset Management LLC purchased a new stake in shares of Endologix, Inc. (NASDAQ:ELGX) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,462,448 shares of the medical instruments supplier’s stock, valued at approximately $17,828,000. Endologix comprises about 2.5% of First Light Asset Management LLC’s investment portfolio, making the stock its 16th biggest position. First Light Asset Management LLC owned approximately 0.14% of Endologix at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its holdings in Endologix by 14.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 71,343 shares of the medical instruments supplier’s stock valued at $517,000 after purchasing an additional 8,936 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Endologix during the second quarter worth $102,000. Northern Trust Corp lifted its holdings in shares of Endologix by 11.8% during the second quarter. Northern Trust Corp now owns 137,879 shares of the medical instruments supplier’s stock worth $998,000 after buying an additional 14,590 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Endologix during the second quarter worth $145,000. Finally, Weiss Asset Management LP acquired a new stake in shares of Endologix during the second quarter worth $187,000. 77.92% of the stock is owned by institutional investors and hedge funds.

ELGX opened at $4.05 on Friday. Endologix, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $22.00. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.53 and a quick ratio of 1.80. The stock has a fifty day moving average of $5.51 and a 200-day moving average of $6.38.

Endologix (NASDAQ:ELGX) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.43. Endologix had a negative return on equity of 120.57% and a negative net margin of 60.32%. The company had revenue of $36.24 million for the quarter, compared to analysts’ expectations of $36.09 million. On average, equities research analysts predict that Endologix, Inc. will post -2.69 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on ELGX shares. ValuEngine raised Endologix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Endologix from a “buy” rating to a “hold” rating in a report on Thursday, September 12th. Finally, Royal Bank of Canada set a $7.00 target price on Endologix and gave the stock a “hold” rating in a report on Friday, August 9th. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $16.30.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Featured Article: Asset Allocation and Your Retirement

Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix, Inc. (NASDAQ:ELGX).

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SPDR Portfolio Short Term Corporate Bond ETF  Shares Sold by Royal Bank of Canada
SPDR Portfolio Short Term Corporate Bond ETF Shares Sold by Royal Bank of Canada
Mackenzie Financial Corp Sells 10,601 Shares of Intuit Inc.
Mackenzie Financial Corp Sells 10,601 Shares of Intuit Inc.
5,800 Shares in Roku Inc  Acquired by Mackenzie Financial Corp
5,800 Shares in Roku Inc Acquired by Mackenzie Financial Corp
Celestica Inc  Shares Sold by Royal Bank of Canada
Celestica Inc Shares Sold by Royal Bank of Canada
Mackenzie Financial Corp Reduces Stock Holdings in China Mobile Ltd.
Mackenzie Financial Corp Reduces Stock Holdings in China Mobile Ltd.
Treasurer of the State of North Carolina Reduces Position in Outfront Media Inc
Treasurer of the State of North Carolina Reduces Position in Outfront Media Inc


© 2006-2019 Ticker Report